Association Between Continued Cannabis Use and Risk of Relapse in First-Episode Psychosis: A Quasi-Experimental Investigation Within an Observational Study
- PMID: 27680429
- DOI: 10.1001/jamapsychiatry.2016.2427
Association Between Continued Cannabis Use and Risk of Relapse in First-Episode Psychosis: A Quasi-Experimental Investigation Within an Observational Study
Abstract
Importance: Cannabis use after first-episode psychosis is associated with poor outcomes, but the causal nature of this association is unclear.
Objective: To examine the precise nature of the association between continued cannabis use after the onset of psychosis and risk of relapse of psychosis.
Design, setting, and participants: This prospective cohort study followed up for at least 2 years after the onset of psychosis 220 patients who presented to psychiatric services in South London, England, from April 12, 2002, to July 26, 2013, with first-episode psychosis. Longitudinal modeling (fixed-effects analysis, cross-lagged path analysis) was used to examine whether the association between changes in cannabis use and risk of relapse over time is the result of shared vulnerability between psychosis and cannabis use, psychosis increasing the risk of cannabis use (reverse causation), or a causal effect of cannabis use on psychosis relapse.
Interventions: Exposure to cannabis within the first and second years after onset of psychosis.
Main outcomes and measures: The main outcome measure was relapse of psychosis, defined as subsequent hospitalization for psychosis. Effect of cannabis use status in the first year (Ct1) and second year (Ct2) and pattern of cannabis use continuation in the first year and second year were modeled for risk of relapse in the first year (Rt1) and risk of relapse in the second year (Rt2) after psychosis onset.
Results: A total of 220 patients with first-episode psychosis were included in the analysis (mean [SD] age, 28.62 [8.58] years; age range, 18-65 years; 90 women [40.9%] and 130 men [59.1%]). Fixed-effects models that adjusted for time-variant (other illicit drug use, antipsychotic medication adherence) and time-invariant (eg, genetic or premorbid environment) unobserved confounders revealed that there was an increase in the odds of experiencing a relapse of psychosis during periods of cannabis use relative to periods of no use (odds ratio, 1.13; 95% CI, 1.03-1.24). Change in the pattern of continuation significantly increased the risk (odds ratio, 1.07; 95% CI, 1.02-1.13), suggesting a dose-dependent association. Cross-lagged analysis confirmed that this association reflected an effect of cannabis use on subsequent risk of relapse (Ct1→Rt2: β = 0.44, P = .04) rather than an effect of relapse on subsequent cannabis use (Rt1→Ct2: β = -0.29, P = .59).
Conclusions and relevance: These results reveal a dose-dependent association between change in cannabis use and relapse of psychosis that is unlikely to be a result of self-medication or genetic and environmental confounding.
Similar articles
-
Poor medication adherence and risk of relapse associated with continued cannabis use in patients with first-episode psychosis: a prospective analysis.Lancet Psychiatry. 2017 Aug;4(8):627-633. doi: 10.1016/S2215-0366(17)30233-X. Epub 2017 Jul 10. Lancet Psychiatry. 2017. PMID: 28705600 Free PMC article.
-
Stressful life events and relapse of psychosis: analysis of causal association in a 2-year prospective observational cohort of individuals with first-episode psychosis in the UK.Lancet Psychiatry. 2023 Jun;10(6):414-425. doi: 10.1016/S2215-0366(23)00110-4. Epub 2023 May 2. Lancet Psychiatry. 2023. PMID: 37146625 Free PMC article.
-
Effects of continuation, frequency, and type of cannabis use on relapse in the first 2 years after onset of psychosis: an observational study.Lancet Psychiatry. 2016 Oct;3(10):947-953. doi: 10.1016/S2215-0366(16)30188-2. Epub 2016 Aug 23. Lancet Psychiatry. 2016. PMID: 27567467
-
[Cannabis and psychosis: search of a causal link through a critical and systematic review].Encephale. 2009 Sep;35(4):377-85. doi: 10.1016/j.encep.2008.02.012. Epub 2008 Jul 9. Encephale. 2009. PMID: 19748375 Review. French.
-
Association Between Cannabis and Psychosis: Epidemiologic Evidence.Biol Psychiatry. 2016 Apr 1;79(7):549-56. doi: 10.1016/j.biopsych.2015.08.001. Epub 2015 Aug 12. Biol Psychiatry. 2016. PMID: 26386480 Review.
Cited by
-
Assessing rates and predictors of cannabis-associated psychotic symptoms across observational, experimental and medical research.Nat Ment Health. 2024;2(7):865-876. doi: 10.1038/s44220-024-00261-x. Epub 2024 Jun 3. Nat Ment Health. 2024. PMID: 39005547 Free PMC article.
-
Rethinking Mental Automatism: De Clérambault's Theory in the Age of Novel Psychoactive Drugs: Psychotropic Effects and Synthetic Psychosis.Healthcare (Basel). 2024 Jun 10;12(12):1172. doi: 10.3390/healthcare12121172. Healthcare (Basel). 2024. PMID: 38921287 Free PMC article.
-
Antipsychotic Use and Psychiatric Hospitalization in First-Episode Non-affective Psychosis and Cannabis Use Disorder: A Swedish Nationwide Cohort Study.Schizophr Bull. 2024 Nov 8;50(6):1287-1294. doi: 10.1093/schbul/sbae034. Schizophr Bull. 2024. PMID: 38534050 Free PMC article.
-
Remission with or without comorbid substance use disorders in early psychosis: long-term outcome in integrated care (ACCESS III study).Front Psychol. 2023 Dec 21;14:1237718. doi: 10.3389/fpsyg.2023.1237718. eCollection 2023. Front Psychol. 2023. PMID: 38187418 Free PMC article.
-
Predictors of relapse and engagement in care one year after ending services in an urban safety net coordinated specialty care program for first episode psychosis.Schizophr Res. 2024 Feb;264:140-146. doi: 10.1016/j.schres.2023.12.022. Epub 2023 Dec 21. Schizophr Res. 2024. PMID: 38128345
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
